Federated Hermes, Inc. Affimed N.V. Transaction History

Federated Hermes, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $4 - $9	2 New	2 $1,000
Q1 2022 May 13, 2022	SELL	$3.69 - $5.65 $13,409 - $20,532	-3,634 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $24,744 - $32,578	-4,608 Reduced 55.91%	3,634 $20,000
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $45,660 - $61,897	8,242 New	8,242 $51,000
Q4 2019 Feb 14, 2020	SELL	$2.25 - $3.07 $74,675 - $101,890	-33,189 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.67 - $3.65 $88,614 - $121,139	33,189 New	33,189 $98,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.